Kazia Therapeutics Propriété institutionnelle
Quel est le Propriété institutionnelle de Kazia Therapeutics?
Le Propriété institutionnelle de Kazia Therapeutics Limited est 14.64%
Quelle est la définition de Propriété institutionnelle?
La propriété institutionnelle est le montant des actions disponibles d'une société détenues par des fonds mutuels ou des fonds de pension, des compagnies d'assurance, des sociétés d'investissement, des fonds de dotation ou d'autres grandes entités qui gèrent des fonds pour le compte de tiers.
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
Propriété institutionnelle des entreprises dans Health Care secteur sur ASX par rapport à Kazia Therapeutics
Que fait Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Entreprises avec propriété institutionnelle similaire à Kazia Therapeutics
- Plus Therapeutics a Propriété institutionnelle de 14.62%
- Irsa Inversiones Y Representaciones S.A a Propriété institutionnelle de 14.62%
- Beforepay Ltd a Propriété institutionnelle de 14.62%
- Investigator Resources a Propriété institutionnelle de 14.63%
- Salzgitter AG a Propriété institutionnelle de 14.63%
- Control Print a Propriété institutionnelle de 14.63%
- Kazia Therapeutics a Propriété institutionnelle de 14.64%
- CT Real Estate Investment Trust a Propriété institutionnelle de 14.64%
- 9 Spokes International a Propriété institutionnelle de 14.65%
- SELLAS Life Sciences Inc a Propriété institutionnelle de 14.65%
- Bharat Wire Ropes a Propriété institutionnelle de 14.65%
- Sienna Senior Living a Propriété institutionnelle de 14.67%
- Block Plc a Propriété institutionnelle de 14.68%